Comparison of DNA hypermethylation of tumor suppressor genes as diagnostic biomarkers in screening and auxiliary detection of breast cancer: an indirect comparison Meta-analysis

doi:10.3969/j.issn.1006-7795.2017.04.014

Abstract

Abstract: Objective To assess the comparative efficacy of diagnostic accuracy of DNA methylation biomarkers for the screening and detection of breast cancer, we conducted an indirect comparison Meta-analysis of published reports. Methods Databases including the Cochrane Library, PubMed, EMbase, Chinese BioMedical Literature Database (CBM), Web of Science, China National Knowledge Infrastructure (CNKI) and WanFang Data were searched to collect the diagnostic trials on the Meta-analysis of aberrant DNA hypermethylation for breast cancer published until October 2016. The indirect comparison Meta-analysis was used to evaluate the diagnostic value of the included genes, and the Meta-analysis was conducted via Review manager 5.3 software. Results Ten Meta-analysis of 130 original studies were included. In summary of Meta-analysis, compared with others gene, methylation of phosphatase and tensin homolog gene (PTEN) ［iodds ratio (OR)=66.16 (24.48-178.82)］, methylation of Runt-related transcription factor 3 gene (RUNX3) ［OR=28.88 (15.48－54.25)］ had greater risk in breast cancer. Although breast cancer 1 gene (BRCA1) ［OR=2.11 (1.88－2.35)］ was the smallest risk for breast cancer, the weight of BRCA1 gene was up to 57.1% in all the Meta. According to the sensitivity, compared with others gene, RUNX3 ［0.62 (0.56－0.67)］ was the largest, followed by fragile histidine triad protein gene (FHIT) ［0.59 (0.54－0.63)］, but the specificity of RUNX3 ［0.95 (0.91-0.97)］ was greater than FHIT ［0.65 (0.61－0.69)］. Comprehensive sensitivity and specificity of ten genes, the largest value of RUNX3 in the diagnosis of breast cancer was found. Conclusion We advocate that RUNX3 and BRCA1 gene methylation can be used in the screening and auxiliary detection of breast cancer.

Key words: breast cancer, methylation, diagnostic test, indirect comparison, Meta-analysis

CLC Number:

R195

Liu Di, Zhao Zhongyao, Sun Qi, Wang Youxin. Comparison of DNA hypermethylation of tumor suppressor genes as diagnostic biomarkers in screening and auxiliary detection of breast cancer: an indirect comparison Meta-analysis[J]. Journal of Capital Medical University, 2017, 38(4): 559-565.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2017.04.014

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2017/V38/I4/559

References

[1] Chen W, Zheng R, Baade P D, et al. Cancer Statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2] Li T, Mello-Thoms C, Brennan P C. Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence[J]. Breast Cancer Res Treat, 2016, 159(3): 395-406.
[3] Mathe A, Wong-Brown M, Locke W J, et al. DNA methylation profile of triple negative breast cancer-specific genes comparing lymph node positive patients to lymph node negative patients[J]. Sci Rep, 2016, 6:33435.
[4] Zhou D, Tang W, Wang W, et al. Association between aberrant APC promoter methylation and breast cancer pathogenesis: a Meta-analysis of 35 observational studies[J]. PeerJ, 2016, 4: e2203.
[5] Wang Y, Qin X, Wu J, et al. Association of promoter methylation of RUNX3 gene with the development of esophageal cancer: a Meta analysis[J]. PLoS One, 2014, 9(9): e107598.
[6] Wu L, Wang F, Xu R, et al. Promoter methylation of BRCA1 in the prognosis of breast cancer: a Meta-analysis[J]. Breast Cancer Res Treat, 2013, 142(3): 619-627.
[7] Jiang Y, Cui L, Chen W D, et al. The prognostic role of RASSF1A rromoter methylation in breast cancer: A Meta-analysis of published data[J]. PLoS One, 2012, 7(5):e367805.
[8] Faryna M, Konermann C, Aulmann S, et al. Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis[J]. FASEB J, 2012, 26(12): 4937-4950.
[9] Guo T, Ren L, Wang Q, et al. A network Meta-analysis of updated haemostatic strategies for hysterectomy[J]. Int J Surg, 2016, 35: 187-195.
[10] 刘国伟,于莉莉,贾洪霞,等. 系统评价中的间接比较与网状Meta分析方法研究进展[J]. 中国循证医学杂志,2014(10): 1276-1280.
[11] 王丹,翟俊霞,牟振云,等. Meta分析中的异质性及其处理方法[J]. 中国循证医学杂志,2009(10): 1115-1118.
[12] Whiting P, Rutjes A W, Reitsma J B, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews[J]. BMC Med Res Methodol, 2003, 3: 25.
[13] Rojas K, Stuckey A. Breast cancer epidemiology and risk factors[J]. Clin Obstet Gynecol, 2016, 59(4): 651-672.
[14] Dai D, Dong X H, Cheng S T, et al. Aberrant promoter methylation of HIN-1 gene may contribute to the pathogenesis of breast cancer: a Meta-analysis[J]. Tumour Biol, 2014, 35(8): 8209-8216.
[15] Huang R, Ding P, Yang F. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a Meta-analysis and literature review[J]. Drug Des Devel Ther, 2015, 9: 5277-5285.
[16] Fang C, Jian Z Y, Shen X F, et al. Promoter methylation of the retinoic acid receptor beta2 (RAR beta2) is associated with increased risk of breast cancer: a PRISMA Compliant Meta-analysis[J]. PLoS One, 2015, 10(10): e140329.
[17] Luo S, Chen J, Mo X. The association of PTEN hypermethylation and breast cancer: a Meta-analysis[J]. Onco Targets Ther, 2016, 9: 5643-5650.
[18] Su Y, Wang X, Li J, et al. The clinicopathological significance and drug target potential of FHIT in breast cancer, a Meta-analysis and literature review[J]. Drug Des Devel Ther, 2015, 9: 5439-5445.
[19] Song X Y, Li B Y, Zhou E X, et al. The clinicopathological significance of RUNX3 hypermethylation and mRNA expression in human breast cancer, a Meta-analysis[J]. Onco Targets Ther, 2016, 9: 5339-5347.
[20] 闫战涛,聂艳红,吴永平,等. 不同乳腺癌分子亚型中RUNX3蛋白表达和启动子的甲基化[J]. 临床与实验病理学杂志,2014,30(1): 10-14.
[21] Xia Y, Zhang M, Zhang X, et al. A systematic review and Meta-analysis of runt-related transcription factor 3 gene promoter hypermethylation and risk of gastric cancer[J]. J Cancer Res Ther, 2014, 10 Suppl: 310-313.
[22] Xu L, Lan H, Su Y, et al. Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a Meta-analysis[J]. Drug Des Devel Ther, 2015, 9: 2855-2865.
[23] 吴丹,董莹,张矛. RUNX3基因启动子区甲基化与肝癌临床病理特征的Meta分析[J]. 临床肿瘤学杂志,2014,19(8): 705-710.
[24] Gross E, van Tinteren H, Li Z, et al. Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study[J]. BMC Cancer, 2016, 16(1): 811.
[25] Weren R D, Mensenkamp A R, Simons M, et al. Novel BRCA1 and BRCA2 tumour test as basis for treatment decisions and referral for genetic counselling of patients with ovarian carcinomas[J]. Hum Mutat, 2017,38(2):226-235.
[26] Huang Y T, Chu S, Loucks E B, et al. Epigenome-wide Profiling of DNA Methylation in Paired Samples of Adipose Tissue and Blood [J]. Epigenetics, 2016, 11(3): 227-236.